MRUS Merus N.V.: institutional ownership and insider trading
Over the last 12 months insiders bought $7.59B and sold $960K on the open market; over its last four quarters it reported revenue of $56.6M and net income of −$381M.
MRUS revenue and earnings
- Quarter ended Sep 30, 2025: revenue $12.2M, net income −$95.5M, EPS -1.26
- Quarter ended Jun 30, 2025: revenue $8.83M, net income −$158M, EPS -2.23
- Quarter ended Mar 31, 2025: revenue $26.5M, net income −$96.5M, EPS -1.40
- Quarter ended Dec 31, 2024: revenue $9.14M, net income −$30.9M, EPS -0.49
Recent MRUS insider trades
- Dec 29, 2025: Genmab A/S bought 76,922,983 shares ($7.46B)
- Dec 26, 2025: Genmab A/S bought 815,444 shares ($79.1M)
- Dec 19, 2025: Genmab A/S bought 278,441 shares ($27.0M)
- Dec 17, 2025: Genmab A/S bought 271,547 shares ($26.3M)
Are insiders buying or selling MRUS?
Over the last 12 months insiders bought $7.59B and sold $960K of Merus N.V. stock on the open market (SEC Form 4).
What was MRUS's revenue last quarter?
Merus N.V. reported revenue of $12.2M for the quarter ended September 30, 2025, with net income of −$95.5M.